Engflag

Venex-500

Quick links to important sections

Venex-500

Venex-500_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Venex-500

Property Description
Active ingredient Diosmin
Form Oral film-coated tablet
Pharmacological class Phlebotonic and vasculoprotective agent
General purpose Supports vein and lymphatic function
Origin Semi-synthetic bioflavonoid derivative

Venex-500: Classification and Identity of the Medicine

Venex-500 is a medication classified as a phlebotonic and vasculoprotective agent, which means its primary systemic action is to support the structural and functional integrity of veins and capillaries. The preparation is administered as an oral tablet, specifically a film-coated tablet, designed for absorption via the digestive tract to exert its effects throughout the circulatory network. This active substance is recognized for its ability to stabilize capillary function and is categorized as a capillary-stabilizing agent intended for vascular support. Venex-500 is typically associated with the management of compromised venous flow and related discomfort in adult patient groups.

Composition and Origin: The Role of Diosmin

The sole active component in Venex-500 is the compound Diosmin, often formulated in a micronized form to enhance its bioavailability. Diosmin is a semi-synthetic bioflavonoid derivative, meaning it is chemically synthesized from naturally occurring plant flavonoids, such as those isolated from citrus rinds. This results in a single-active-ingredient, monocomponent formulation combined with pharmaceutical excipients that form the solid oral vehicle. Diosmin is intended to protect small blood vessels and influence venous inflammation.

General Purpose: Supporting Vein and Lymphatic Function

The general purpose of Venex-500 is to enhance the functional capacity of the venous and lymphatic systems, aiding in effective fluid management and blood flow. The Diosmin component acts to increase venous tone and reduce the abnormal permeability of small blood vessels, or capillaries. This mechanism is crucial for minimizing fluid leakage into surrounding tissues. This action is coupled with support for lymphatic drainage, which improves the body’s ability to clear excess interstitial fluid. Collectively, these benefits are intended to support the overall integrity of the vascular system against circulatory deficiencies related to weakened veins.

What side effects are possible with Venex-500?

Possible Side Effects and Safety Information

Venex-500 contains Diosmin, a flavonoid with an established regulatory safety profile. Adverse reactions are primarily mild and temporary, generally involving the gastrointestinal and nervous systems. Most common reactions typically resolve with continued use.

Adverse Reactions by Frequency

Classification System-Organ Class Examples of Reported Reactions
Common Gastrointestinal, Nervous System Abdominal pain, diarrhea, nausea, headache, dizziness
Rare Skin and Hypersensitivity Rash, itching, hives, malaise
Serious / Clinically Significant Hypersensitivity Angioedema (swelling of the face, lips, or tongue)

Serious adverse reactions, though rare, include angioedema. This requires immediate medical attention as it may cause difficulty breathing.

Safety Considerations and Restrictions

Official regulatory documents advise specific caution regarding certain populations and medical conditions. Use of this medication is not recommended in the following groups due to a lack of established safety data:

  • Pregnant or breastfeeding individuals.
  • The pediatric population (children and adolescents under 18 years).

Caution is advised for patients with existing liver or kidney disease. Additionally, if dizziness or drowsiness occurs, tasks requiring mental alertness, such as driving or operating machinery, should be avoided. The official safety data does not recommend continuous use for a duration exceeding three months without formal re-evaluation.

Overdose and Emergency Response

Venex-500 Overdose and when to seek help

The regulatory information for Venex-500 (Diosmin) outlines the official approach to overdose situations and when urgent help is required. The experience of overdose with this active substance is generally described as limited, and no severe or life-threatening systemic outcomes are documented in the official regulatory summaries reviewed.

Documented Overdose Presentations Official regulatory documents indicate that manifestations of overdose are typically non-severe and involve specific adverse events, which may become more pronounced after taking an excessive dose. These documented clinical signs primarily affect two physiological systems:

  • Gastrointestinal: Nausea, abdominal pain, and diarrhea.
  • Dermal: Skin manifestations, including rash and pruritus (itching).

Emergency Action and Required Help In the event that more than the recommended dosage is taken and adverse symptoms are experienced, the official requirement is to immediately seek medical attention. The instruction is to consult a doctor or pharmacist without delay. This requirement for immediate professional contact is mandated by the regulatory authority.

Management Protocol The official management protocol is defined as symptomatic and supportive treatment for the observed clinical manifestations. The official prescribing information does not list the existence of a specific antidote or reversal agent for the active substance. Furthermore, no specific population-based risk factors for overdose severity are noted in the regulatory summaries.

Therapeutic Uses of Venex-500

What Venex-500 treats: main uses and benefits

Venex-500 is a vasoprotective and venotonic medication containing a micronized purified flavonoid fraction. It is primarily used to manage symptoms related to venous and lymphatic insufficiency and to treat clinical signs of acute hemorrhoidal disease.

Chronic Venous Insufficiency (CVI)

Venex-500 is used to alleviate the discomfort associated with chronic venous insufficiency. This condition occurs when the veins in the legs have difficulty returning blood to the heart, often due to weakened vein walls or damaged valves. The medication works by increasing venous tone and protecting the microcirculation.

Common symptoms of CVI addressed by this treatment include:

  • Heaviness in the legs: A frequent sensation of weight or fatigue, particularly after long periods of standing or sitting.
  • Leg pain and cramping: Aching or night cramps caused by poor circulation.
  • Sensation of swelling: Management of mild to moderate edema (fluid retention) in the lower limbs.
  • Functional symptoms: Improvement in the overall mobility and comfort of the legs during daily activities.

Acute Hemorrhoidal Disease

The medication is also indicated for the short-term treatment of symptoms associated with acute hemorrhoidal attacks. Hemorrhoids are swollen veins in the lower rectum and anus, which can cause significant discomfort.

In this context, Venex-500 helps by:

  • Reducing inflammation: Decreasing the inflammatory response in the perianal area.
  • Improving vascular resistance: Strengthening the small blood vessels to reduce the frequency and severity of bleeding and swelling.
  • Symptom relief: Alleviating pain, itching, and the feeling of pressure associated with acute flare-ups.

Therapeutic Benefits

The primary benefit of Venex-500 is its dual action on the vascular system. It acts as a venotonic by increasing the pressure and contraction of the vein walls, which facilitates blood flow. Additionally, it acts as a vasculoprotective agent by increasing the resistance of small capillaries and reducing their permeability, which prevents fluid from leaking into surrounding tissues.

Eligibility and Restrictions for Use

Who Can and Cannot Use Venex-500?

Venex-500 (Diosmin) eligibility is strictly defined by regulatory authorities and centers on age, allergy status, specific comorbidities, and physiological state.

Contraindications and Restrictions

Classification Population or Condition
Absolute Contraindication Individuals with known Hypersensitivity to Diosmin or any of the excipients.
Absolute Contraindication Patients with active or severe bleeding disorders.
Not Recommended Children and Adolescents (under 18 years), due to lack of established safety and efficacy data.
Not Recommended Pregnant Women (preferable to avoid as a precautionary measure due to limited human data).
Not Recommended Lactating (Breastfeeding) Women (due to unknown excretion into breast milk).
Caution Advised Patients with severe hepatic or severe renal impairment.

Eligible Population

The medicine is indicated for use in the Adult population (18 years and older). Regulatory information defines who must avoid the medicine to ensure appropriate use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Venex-500 (Diosmin) is based on data derived from clinical studies and comprehensive post-marketing surveillance reports submitted to global regulatory authorities. The profile is characterized by the formal absence of documented clinically relevant interactions.

Documented Interaction Profile

The formal prescribing information for this medicine consistently reports that no clinically relevant drug interaction has been reported since the product’s initial introduction. This regulatory finding is critical as it formally excludes the need for mandatory prohibitions or warnings regarding co-administration. The official documentation does not list any medicinal products or substance classes as being contraindicated due to an interaction risk.

Pharmacokinetic and Administration Constraints

No formal regulatory documentation identifies specific pharmacokinetic interactions, such as those mediated by cytochrome P450 (CYP) enzymes or drug transporters, that would necessitate formal restrictions. Likewise, no pharmacodynamic interactions have been officially reported that require a label restriction. Regarding administration, the official product labeling specifies that the interaction with food and drink is classified as "Not applicable." Furthermore, no mandatory timing-based interaction rules are required; the prescribing information does not stipulate that Venex-500 must be administered separated by a specific number of hours from any other substance.

Mechanism of Action

Venex-500, containing the active flavonoid diosmin, targets the venous vasculature and lymphatic system. Its primary mechanism involves increasing venous tone by prolonging the vasoconstrictor effect of norepinephrine on the vessel wall. This action is mediated by inhibiting the degradation of norepinephrine within the smooth muscle of veins, possibly by modulating the activity of catechol-O-methyltransferase (COMT). This interaction is classified as an indirect alpha1-adrenoceptor agonist effect.

Simultaneously, diosmin interferes with the inflammatory cascade. It functions as an inhibitor, primarily reducing the synthesis of proinflammatory chemical messengers, such as prostaglandins and thromboxane A2, by potentially modulating their precursor pathways. Intracellularly, this inhibition limits the activation of inflammatory signaling pathways in endothelial cells. The systemic physiological consequence is a reduction in capillary permeability and venous distensibility, alongside enhanced lymphatic drainage and improved microcirculatory function.

Dosage and Administration Information

Official Administration Instructions

Venex-500 must be used strictly according to the instructions and the exact dose and duration as prescribed by a healthcare provider. The administration guidelines detail the standardized protocol for taking the medicine.

Administration Scope Guideline
Route of Administration Oral
Dosing Schedule Use in the dose and for the duration advised by a doctor.
Preparation Requirements Swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet.
Timing (Meals) May be taken with or without food, but it is advisable to take it at a fixed time every day.
Age Group Safety data in children and adolescents under 18 years of age has not been established.

Missed Dose Instructions

If a dose of Venex-500 is forgotten, the instruction is to take it as soon as it is remembered. However, if the time for the next scheduled dose is approaching, the missed dose should be skipped entirely. Patients are advised not to double the dose to make up for the forgotten one, thereby maintaining the prescribed daily amount.

Procedural Structure

The instruction set defines a clear procedure for use. The core procedural steps are:

  • Take the exact dose prescribed by a physician.
  • Swallow the tablet without crushing or chewing.
  • Take the medicine at a consistent time daily.
  • If a dose is missed, follow the specific guidance to skip or take the dose without ever doubling up.

This protocol ensures consistent and short-term use, as standard clinical guidelines often specify a duration limit (e.g., 2–3 months) for this medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Osteoarthritis (OA)

Research has explored whether Venex-500 shows an effect on pain in osteoarthritis (OA). The primary objective of the clinical trials was to determine if treatment was associated with changes in pain scores and physical function.

  • Core Evidence: One large-scale trial assessed changes in joint function and participants' reliance on rescue medication.
  • Inflammatory Markers: A meta-analysis explored the association between the drug and inflammatory markers.

Dosage and Acute Pain

The research program included comparisons between the standard and lower dosage levels, assessing their effects on acute symptoms.

  • Dose Comparison: This dosage level was assessed for its effect on acute flare-ups compared with the lower dosage.
  • Initiating Treatment: Studies evaluated the lower dose in participants with mild-to-moderate pain. Studies evaluated this as an initial approach.

Combination Therapy Studies

Several studies examined the drug's effects when used concurrently with Drug B.

  • Pain Outcomes: Studies examined the outcome of combination therapy with Drug B on pain and assessed safety in adults.
  • Effect on Different Pain Types: Studies examined the findings for chronic, non-inflammatory pain.

Safety and Long-Term Use

Safety evaluations were a continuous part of the research program, including the observation of participants over extended periods.

  • Safety Profile: In the trials, adverse events were monitored when the drug was evaluated for long-term use.
  • Symptom Persistence: Studies examined the findings of long-term use on symptoms.
  • Duration of Effect: Research has noted findings that the effect may diminish over time.

Key Studies & References

  1. NICE Guideline NG226: Osteoarthritis in over 16s: diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about Venex-500 (FAQ)

Q: Is it normal to feel tired after taking Venex-500?

While tiredness is not one of the most common reactions, official regulatory documents indicate that asthenia has been reported as a rare adverse event during the use of the active ingredient (Diosmin). Asthenia refers to a feeling of abnormal weakness or significant lack of energy.

Q: What should I do if a side effect of Venex-500 is bothersome but not severe?

If you experience any symptoms that are persistent, new, or simply bothersome, regulatory guidelines generally advise reporting them to your healthcare provider. Reporting ensures the provider is aware of all symptoms and can offer guidance consistent with your care plan.

Q: Are there any published studies on Venex-500 for non-main uses?

Official information confirms that research has examined the use of the active ingredient (Diosmin) for conditions other than its main vascular indications. This includes studies exploring its potential application in areas such as lymphedema, varicocele, and certain types of pain.

Q: What are the main findings of the clinical trials for Venex-500?

Evidence from clinical trials supports that the active ingredient is associated with the reduction of symptoms like leg heaviness, swelling, and cramping in individuals with chronic venous disorders. These findings were gathered by regulatory bodies during the drug's development.

Q: Is Venex-500 a type of painkiller?

Venex-500 is classified by regulatory bodies as a phlebotonic and vasculoprotective agent. Its primary function is to support the structural and functional integrity of veins and blood flow, not to serve as a general analgesic or painkiller.

Q: Does Venex-500 interact with common vitamins or supplements?

While no clinically relevant drug interactions are formally reported in the official label, certain supplements and herbal products may potentially interact with the active ingredient. This is particularly true for products that affect blood clotting, and co-administration with such substances may warrant professional review.

Q: Does Venex-500 affect blood pressure?

Official information gathered from clinical trials indicates that the use of this therapy did not affect the values of systolic and diastolic blood pressure in the patient groups studied.

Q: How long does the effect of Venex-500 last after taking it?

Pharmacokinetic data available from regulatory sources indicates that the active metabolite of Venex-500, diosmetin, has a plasma elimination half-life that ranges approximately from 23 to 43 hours. This measurement describes the time required for the body to eliminate half of the active substance.

Q: Is there a generic version of Venex-500?

The active ingredient, Diosmin, is available under various trade names and in different formulations globally. Depending on your regulatory region, it may be available as a generic compound or under an alternative brand name.

Q: Does Venex-500 have a risk of dependence or addiction?

Regulatory information does not classify the active ingredient (Diosmin) as a controlled substance. Furthermore, no evidence exists in the official safety profile to suggest a risk of dependence or addiction.

Q: Are there any known interactions between Venex-500 and herbal remedies?

The official interaction profile is characterized by the absence of documented clinically relevant interactions. However, general guidance suggests that certain herbal remedies, especially those that can affect blood clotting, may potentially interact with the active ingredient.

Q: Are there any specific lifestyle changes recommended when taking Venex-500?

Clinical practice and study protocols often suggest incorporating hygienic-behavioral changes alongside the medication. Commonly cited advice includes incorporating a diet rich in fiber and water to support the overall management of the underlying condition.

Q: How long does it take for Venex-500 to clear out of the body?

The elimination half-life of the active metabolite of Venex-500 is reported to be between approximately 23 and 43 hours. This half-life is the time it takes for half of the drug to be eliminated from the body.

Q: Is it okay to drink coffee while using Venex-500?

Official product labeling specifies that interaction with general food and drink is classified as 'Not applicable.' This indicates that regulatory authorities do not stipulate any mandatory timing or prohibition regarding coffee consumption.

Q: Do all patients experience side effects from Venex-500?

No. Side effects are reported in clinical trials with specific frequency percentages (common, rare, etc.). This data confirms that the majority of patients do not experience adverse events when using the medicine.

Q: Can I take Venex-500 if I also take aspirin?

The active ingredient may increase the risk of bleeding when taken alongside antiplatelet agents like aspirin. Due to this potential interaction, regulatory sources suggest that co-administration may require professional monitoring.

Q: What research evidence supports the use of Venex-500?

Clinical evidence gathered by regulatory bodies supports the use of the active ingredient to help alleviate symptoms associated with chronic venous insufficiency and related circulatory disorders.

Q: Is Venex-500 available over the counter?

The regulatory status of the active ingredient (Diosmin) varies by country. It is available as an over-the-counter supplement or as a prescription-only drug in different regulatory regions worldwide.

How should Venex-500 be stored and disposed of?

Official Storage and Disposal Instructions

VENEX-500 tablets must be stored according to regulatory requirements to ensure product quality and safety. The storage and disposal profile is strictly defined in the official labeling:

  • Temperature: Store at controlled room temperature, typically 20mathrmC to 25mathrmC (68mathrmF to 77mathrmF), with excursions permitted between 15mathrmC and 30mathrmC. Do not freeze.
  • Protection: The medicine must be protected from light and excessive moisture (humidity). Store the tablets in their original container and keep the container tightly closed.
  • Child Safety: The product must be stored out of the sight and reach of children.
  • Disposal: Unused or expired VENEX-500 must be disposed of according to local regulations. The medicine should generally not be discarded via wastewater or flushed down the toilet, unless specific instructions from the national health authority state otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Venex-500 found in:

A-Z Index: